Plenary Speakers Prof Margaret Brimble
Margaret is a Distinguished Professor and Director of Medicinal Chemistry at the University of Auckland, New Zealand. She is an Executive Editor for Organic Letters, Deputy Director of the Maurice Wilkins Centre for Molecular Biodiscovery, Past-President of IUPAC Organic and Biomolecular Division III and Past-President of the International Society of Heterocyclic Chemistry. She has published >580 papers, 100 reviews and is an inventor on >50 patents. She is a Fellow of the Royal Society London, Dame Companion of the New Zealand Order of Merit and was inducted into the American Chemical Society Medicinal Chemistry Hall of Fame. She was awarded the 2023 Davy Medal from the Royal Society London, Rutherford, Hector and MacDiarmid medals (Royal Society NZ), 2022 Royal Society of Chemistry Pedler Award for innovation in Organic Chemistry and the 2023 American Chemical Society Ernest Guenther award for Natural Products Chemistry. She was also named the 2007 L’Oreal-UNESCO Women in Science laureate in Materials Science for Asia-Pacific and a 2015 IUPAC Distinguished Women in Chemistry/Chemical Engineering. Margaret’s research focusses on the synthesis of novel bioactive natural products, antimicrobial and antiviral peptides, antibody-drug conjugates, lipopeptides/glycopeptides for vaccines and new biomaterials. Her lab carried out the medicinal chemistry programme that led to the discovery of the drug Trofinetide (NNZ2566) that gained FDA approval (marketed as DaybueTM) in March 2023 for the treatment of Rett Syndrome (http://www. neurenpharma.com; https://acadia.com). Her team also carried out the medicinal chemistry for the investigational new drug candidate NNZ2591 that is currently in phase 2 clinical trials for four neurogenetic disorders: Angelman syndrome, Pitt Hopkins syndrome, Phelan-McDermid syndrome and Prader-Willi syndrome.
Made with FlippingBook Learn more on our blog